107 related articles for article (PubMed ID: 7406947)
1. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver.
Hanefeld M; Kemmer C; Leonhardt W; Kunze KD; Jaross W; Haller H
Atherosclerosis; 1980 Jun; 36(2):159-72. PubMed ID: 7406947
[TBL] [Abstract][Full Text] [Related]
2. [Induction of fatty acid oxidation in peroxisomes of rat liver by magnesium-4 chlorophenoxyisobutyrate (Mg-CPIB)].
Paltauf F; Magnet K
Arzneimittelforschung; 1979; 29(8):1132-4. PubMed ID: 583010
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro peroxisome proliferation properties of selected clofibrate analogues in the rat. Structure-activity relationships.
Esbenshade TA; Kamanna VS; Newman HA; Tortorella V; Witiak DT; Feller DR
Biochem Pharmacol; 1990 Sep; 40(6):1263-74. PubMed ID: 2403380
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term administration of clofibric acid on peroxisomal beta-oxidation, fatty acid-binding protein and cytosolic long-chain acyl-CoA hydrolases in rat liver.
Kawashima Y; Katoh H; Watanuki H; Takegishi M; Kozuka H
Biochem Pharmacol; 1985 Feb; 34(3):325-9. PubMed ID: 2857564
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of enzyme induction by peroxisome proliferators and application to determination of effects on triglyceride biosynthesis in primary cultures of rat hepatocytes.
Kocarek TA; Feller DR
Biochem Pharmacol; 1989 Dec; 38(23):4169-76. PubMed ID: 2597188
[TBL] [Abstract][Full Text] [Related]
6. Effect of clofibrate on lipid metabolism in streptozotocin diabetic rats.
Cayen MN; Dubuc J; Dvornik D
Proc Soc Exp Biol Med; 1975 Mar; 148(3):752-7. PubMed ID: 165533
[TBL] [Abstract][Full Text] [Related]
7. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man.
Hanefeld M; Kemmer C; Kadner E
Atherosclerosis; 1983 Feb; 46(2):239-46. PubMed ID: 6838704
[No Abstract] [Full Text] [Related]
8. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
9. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
Herrera E; Lasunción MA; Castro M; Gómez-Coronado D; Martín A; Quack G
Biochim Biophys Acta; 1988 Nov; 963(1):42-52. PubMed ID: 3179329
[TBL] [Abstract][Full Text] [Related]
10. The immediate and long term effects of clofibrate on the metabolism of the perfused rat liver.
Laker ME; Mayes PA
Biochem Pharmacol; 1979 Sep; 28(18):2813-27. PubMed ID: 497030
[No Abstract] [Full Text] [Related]
11. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
[TBL] [Abstract][Full Text] [Related]
12. Modification by clofibric acid of acyl composition of glycerolipids in rat liver. Possible involvement of fatty acid chain elongation and desaturation.
Kawashima Y; Hirose A; Kozuka H
Biochim Biophys Acta; 1984 Oct; 795(3):543-51. PubMed ID: 6477960
[TBL] [Abstract][Full Text] [Related]
13. [Research regarding the action of a derivative of the clofibric acid series on lipid metabolism].
Filip M; Păduraru I; Hriscu A; Neacşu R; Dănilă G; Filip F
Rev Med Chir Soc Med Nat Iasi; 1987; 91(2):341-5. PubMed ID: 3685700
[No Abstract] [Full Text] [Related]
14. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
Vessby B; Lithell H; Hellsing K; Ostlund-Lindqvist AM; Gustafsson IB; Boberg J; Ledermann H
Atherosclerosis; 1980 Oct; 37(2):257-69. PubMed ID: 7000090
[No Abstract] [Full Text] [Related]
15. Hypolipemic activity of plafibride.
Bruseghini L; Vilageliu J; Bagaria A
Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
[TBL] [Abstract][Full Text] [Related]
16. [Hypolipidemic activity of glycine and its derivatives].
Ryzhenkov VE; Molokovskiĭ DS; Ioffe DV
Vopr Med Khim; 1984; 30(2):78-80. PubMed ID: 6740998
[TBL] [Abstract][Full Text] [Related]
17. Hypocholesterolaemia in the rat after p-chlorophenoxyisobutyric acid (CPIB) administration as a synthetic triglyceride, 1,3-dipalmitoyl 2(p-chlorophenoxyisobutyroyl)-rac-glycerol.
Owen JS; Billimoria JD
Clin Chim Acta; 1977 Sep; 79(2):349-56. PubMed ID: 890970
[TBL] [Abstract][Full Text] [Related]
18. The short- and long-term effects of bezafibrate in the rat.
Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
[TBL] [Abstract][Full Text] [Related]
19. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term administration of clofibric acid on stearoyl-CoA desaturase, 1-acylglycerophosphorylcholine acyltransferase and fatty acyl composition of microsomal phosphatidylcholine in rat liver.
Hirose A; Kawashima Y; Kozuka H
Biochem Pharmacol; 1987 Apr; 36(8):1209-14. PubMed ID: 2885002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
